Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacokinetics of rilmenidine.

E Singlas1, J D Ehrhardt, P Zech

  • 1C.H.U. du Kremlin-Bicêtre, Faculté de Médecine, Strasbourg, France.

The American Journal of Cardiology
|February 24, 1988
PubMed
Summary

Rilmenidine pharmacokinetics are altered in elderly and renally impaired patients. Dosage adjustments are recommended for severe renal failure to ensure patient safety and treatment efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gamma hydroxybutyrate distribution and turnover rates in discrete brain regions of the rat.

Neurochemistry international·2010
Same author

Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers.

European journal of drug metabolism and pharmacokinetics·2004
Same author

I(1) imidazoline receptors involved in cardiovascular regulation: where are we and where are we going?

Annals of the New York Academy of Sciences·2004
Same author

[Compensatory hyperfunction in living kidney donors].

Nephrologie·2002
Same author

Human pharmacokinetics of a perfluorocarbon ultrasound contrast agent evaluated with gas chromatography.

Ultrasound in medicine & biology·2001
Same author

Sputum itraconazole concentrations in cystic fibrosis patients.

Antimicrobial agents and chemotherapy·2001

Area of Science:

  • Pharmacology
  • Clinical Pharmacy

Background:

  • Rilmenidine is an alpha 2-adrenoceptor agonist primarily eliminated by the kidneys.
  • Understanding its pharmacokinetic profile in various patient populations is crucial for safe and effective dosing.

Purpose of the Study:

  • To investigate the impact of hypertension, aging, renal insufficiency, and hepatic insufficiency on the pharmacokinetic parameters of rilmenidine.
  • To establish dose-adjustment guidelines for specific patient groups.

Main Methods:

  • Single-dose pharmacokinetic studies of rilmenidine (1 mg) were conducted in hypertensive, elderly hypertensive, renal insufficient, and hepatic insufficient patients.
  • Analysis of absorption, distribution, and elimination parameters, including clearance and half-life.

Main Results:

  • Hypertension did not affect rilmenidine absorption, distribution, or elimination; linearity and lack of accumulation were confirmed.
  • In elderly patients, delayed absorption, reduced volume of distribution, decreased clearance, and prolonged half-life were observed.
  • Renal impairment showed linear relationships with elimination parameters, enabling prediction of steady-state levels.
  • Hepatic insufficiency led to a ~20% decrease in apparent clearance.

Conclusions:

  • Rilmenidine dosage requires reduction in patients with severe renal failure.
  • Pharmacokinetic changes in elderly and renally impaired individuals necessitate careful consideration for optimal therapeutic outcomes.

Related Experiment Videos